

## PRESS RELEASE

07 February 2025 08:00:00 CET

### Saniona to give a live interview on Tuesday February 11

**Saniona, a clinical-stage biopharmaceutical company, announces that the company's CEO, Thomas Feldthus, together with Saniona's proposed Chairman, John Haurum, will be interviewed by Bistock on Tuesday, February 11th at 11:00 am CET.**

The Biostock interview is an opportunity to learn more about Saniona's exciting journey and have your questions answered live.

Tune in to the live interview with Saniona on Tuesday, February 11th, at 11:00 am CET, available at [https://youtube.com/live/Df\\_VE2nly5Q?feature=share](https://youtube.com/live/Df_VE2nly5Q?feature=share). During the session, CEO Thomas Feldthus and board member John Haurum (proposed new Chairman) will present the company's strategy and vision while viewers will have the opportunity to engage by asking questions. Questions can be submitted in two ways:

- During the live stream via the YouTube comment section.
- In advance by emailing [redaktion@biostock.se](mailto:redaktion@biostock.se) no later than 10:00 am CET on February 11.

#### For more information, please contact

Thomas Feldthus, CEO, +45 22109957; [thomas.feldthus@saniona.com](mailto:thomas.feldthus@saniona.com)

#### About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona's epilepsy pipeline includes SAN2219, targeting acute repetitive seizures; and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine for obesity is Saniona's most advanced candidate and is out licensed to Medix in Mexico and Argentina. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, visit [www.saniona.com](http://www.saniona.com).

#### Attachments

**Saniona to give a live interview on Tuesday February 11**